Scitech Development, Inc.

Scitech Development, Inc. company information, Employees & Contact Information

SciTech Development, Inc. A clinical-stage, specialty oncology pharmaceutical company Revolutionizing how safe and promising yet challenged drugs can be delivered to kill cancer ST-001 nanoFenretinide: Lead Drug Candidate in Clinical Trials With innovative science and advanced nanotechnology, SciTech has developed ST-001 nanoFenretinide, a patented new drug with clinical trials in progress for T-cell lymphoma (a form of non-Hodgkin lymphoma). FDA has granted Orphan Drug Designation, allowing 7 years of market exclusivity once approved. ST-001 Clinical Trials Update ► Confirmed partial response and stable disease observed ► Preliminary data supports that ST-001 is safe and tolerable at escalating dose levels and has shown efficient delivery of therapeutic doses ► Trial completion for Phase 1a accelerated is targeted for December 2024 ► Small cell lung cancer trial expected to begin Q2 2025 ► NCI provided additional ~$1M gratis supply of fenretinide to dose 300+ patients, complete Phase 1a/b trials, and expand clinical trials"

Company Details

Employees
10
Address
281 Kercheval Avenue, Grosse Pointe Farms,mi 48236,united States
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Grosse Pointe Farms, MI
Looking for a particular Scitech Development, Inc. employee's phone or email?

Scitech Development, Inc. Questions

Top Scitech Development, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant